Progressive pulmonary fibrosis: an expert group consensus statement

Sujeet K. Rajan1, Vincent Cottin2, Raja Dhar3, Sonye Danoff4, Kevin R. Flaherty5, Kevin K. Brown6, Anant Mohan7, Elizabeth Renzoni8, Murali Mohan9, Zarrin Udwadia10, Padmanabha Shenoy11, David Currow12, Anand Devraj13, Bhavin Jankharia14, Ritu Kulshrestha15, Steve Jones16, Claudia Ravaglia17, Silvia Quadrelli18, Rajam Iyer19, Sahajal Dhoooria20, Martin Kolb21,23 and Athol U. Wells22,23

1Bombay Hospital Institute of Medical Sciences and Bhatia Hospital, Mumbai, India. 2National French Reference Coordinating Center for Rare Pulmonary Diseases, Louis Pradel Hospital Hospices Civils de Lyon, Université Claude Bernard Lyon 1, INRAE, Member of ERN-LUNG, Lyon, France. 3CK Birla Hospitals, Kolkata, India. 4Johns Hopkins School of Medicine, Baltimore, MD, USA. 5University of Michigan, Ann Arbor, MI, USA. 6Department of Medicine, National Jewish Health, Denver, CO, USA. 7All India Institute of Medical Sciences, New Delhi, India. 8Royal Brompton Hospital/Imperial College London, London, UK. 9Narayana Health, Bengaluru, India. 10Breach Candy Hospital, Mumbai, India. 11Department of Rheumatology, Centre for Arthritis and Rheumatism Excellence, Kochi, India. 12University of Technology, Sydney, Australia. 13Department of Radiology, Royal Brompton Hospital, London, UK. 14Picture This by Jankharia, Mumbai, India. 15Department of Pathology, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India. 16European Idiopathic Pulmonary Fibrosis Federation (EU-IPFF), Peterborough, UK. 17Pulmonology Unit, GB Morgagni Hospital/University of Bologna, Forlì, Italy. 18Hospital Britanico de Buenos Aires, Buenos Aires, Argentina. 19Bhatia Hospital and PD Hinduja Hospital, Mumbai, India. 20Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India. 21Firestone Institute for Respiratory Health, St Joseph’s Healthcare and McMaster University, Hamilton, ON, Canada. 22Interstitial Lung Disease Unit, Royal Brompton and Harefield NHS Foundation Trust, London, UK. 23Co-senior authors.

Corresponding author: Sujeet K. Rajan (skrajan@hotmail.com)

Shareable abstract (@ERSpublications)
Progressive pulmonary fibrosis (PPF) explains what clinicians increasingly face in practice. Assessing ILD progression, its risk and improved treatments based on current evidence for PPF (despite initial management) form the mainstay of this document.


This single-page version can be shared freely online.

Abstract
This expert group consensus statement emphasises the need for standardising the definition of progressive fibrosing interstitial lung diseases (F-ILDs), with an accurate initial diagnosis being of paramount importance in ensuring appropriate initial management. Equally, case-by-case decisions on monitoring and management are essential, given the varying presentations of F-ILDs and the varying rates of progression. The value of diagnostic tests in risk stratification at presentation and, separately, the importance of a logical monitoring strategy, tailored to manage the risk of progression, are also stressed. The term “progressive pulmonary fibrosis” (PPF) exactly describes the entity that clinicians often face in practice. The importance of using antifibrotic therapy early in PPF (once initial management has failed to prevent progression) is increasingly supported by evidence. Artificial intelligence software for high-resolution computed tomography analysis, although an exciting tool for the future, awaits validation. Guidance is provided on pulmonary rehabilitation, oxygen and the use of non-invasive ventilation focused specifically on the needs of ILD patients with progressive disease. PPF should be differentiated from acute deterioration due to drug-induced lung toxicity or other forms of acute exacerbations. Referral criteria for a lung transplant are discussed and applied to patient needs in severe diseases where transplantation is not realistic, either due to access limitations or transplantation contraindications. In conclusion, expert group consensus guidance is provided on the diagnosis, treatment and monitoring of F-ILDs with specific focus on the recognition of PPF and the management of pulmonary fibrosis progressing despite initial management.